Back to News
Market Impact: 0.32
Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology
Source: PR Newswire
Healthcare & BiotechArtificial IntelligenceTechnology & Innovation
Earendil Labs announced a research collaboration with Genentech, part of Roche Group, to discover and develop multiple therapeutic bispecific antibodies. The deal validates Earendil's AI-powered biologics platform and could expand its drug-development pipeline, though no financial terms, program targets, or timelines were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Japan approval, a 27% surge: the diagnostics stock our models picked in September
- Trump Versus Xi: How Their High-Stakes Summits Compare
- Trump, Xi Address AI, Taiwan During State Visit
- SEBI Allows Portfolio Managers to Invest Overseas, Short Equity Options
- China's Xi urges U.S. to cooperate on AI
- Oracle Japan shares surge 7% after record fiscal first quarter, bucking selloff of U.S. parent
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- Alternative Data Due Diligence for Institutional Investors